| Species |
Human |
| Protein Construction |
CX3CL1/Fractalkine (Gln25-Gln341)
Accession # AAH01163 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
34.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 90-110 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Fractalkine/CX3C chemokine ligand 1 (CX3CL1) is a chemokine involved in the anticancer function of lymphocytes-mainly NK cells, T cells and dendritic cells. Its increased levels in tumors improve the prognosis for cancer patients, although it is also associated with a poorer prognosis in some types of cancers, such as pancreatic ductal adenocarcinoma. |
| Synonyms |
Fractalkine; Neurotactin; Cx3cl1; Cx3c; Fkn; ABCD-3; C3Xkine; CXC3; CXC3C; NTN; NTT; SCYD1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
